Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02713243 · ClinicalTrials.gov registry record · Phase 2
To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.
A Phase 2 study of Primary Bile Acid Diarrhea, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 4
- Study locations
NCT02713243: Completed Phase 2 study of Primary Bile Acid Diarrhea, sponsored by Novartis Pharmaceuticals.
NCT02713243 is a Phase 2 study of Primary Bile Acid Diarrhea that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02713243, a Phase 2 study of Primary Bile Acid Diarrhea, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine whether LJN452 improves the symptoms of bile acid diarrhea and to assess its safety and tolerability profile in patients with primary bile acid diarrhea (pBAD) to guide decision-making regarding further clinical development in this indication.
Primary Outcome
Number of patients reported with adverse events , serious adverse events and death.
Conditions Studied
Interventions
- DRUG LJN452
- DRUG Placebo to LJN452
Study Locations (4)
Other
- Novartis Investigative Site - London
- Novartis Investigative Site - Sheffield
Minnesota
- Novartis Investigative Site - Rochester
Middlesex
- Novartis Investigative Site - Harrow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-01-16 |
| Est. Completion | 2018-01-25 |
| Phase | Phase 2 |
What the finished NCT02713243 record still lists
NCT02713243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Primary Bile Acid Diarrhea appearing as the primary indexed condition, and to 2 interventions - of which LJN452 is the first listed.
NCT02713243 reports a single indexed study location in Other, Minnesota, Middlesex.
Frequently Asked Questions
What is clinical trial NCT02713243 about?
NCT02713243 is a clinical study titled "To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.". The purpose of this study is to determine whether LJN452 improves the symptoms of bile acid diarrhea and to assess its safety and tolerability profile in patients with primary bile acid diarrhea (pBAD) to guide decision-making regarding further clinical development in this indication.
What is the current status of trial NCT02713243?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-01-16. Estimated completion is 2018-01-25.
What conditions does trial NCT02713243 study?
This clinical trial studies the following conditions: Primary Bile Acid Diarrhea.
What interventions are being tested in trial NCT02713243?
The interventions under investigation include: LJN452 (DRUG), Placebo to LJN452 (DRUG).
Who is sponsoring clinical trial NCT02713243?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02713243 being conducted?
This trial has 4 study locations across Minnesota, Middlesex. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02713243's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI